Benitec Biopharma Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BNTC Nasdaq 2834 benitec.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Benitec Biopharma Inc.

Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock - Jan 13th, 2025 2:49 pm
Hedge funds investors own a significant stake of 38% in Benitec Biopharma Inc. (NASDAQ:BNTC) - Dec 18th, 2024 3:18 pm
Benitec Biopharma initiated with a Buy at H.C. Wainwright - Dec 17th, 2024 11:25 am
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? - Dec 9th, 2024 2:55 pm
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why - Dec 9th, 2024 1:50 pm
Benitec Biopharma to Participate in Upcoming Investor Conferences in December - Nov 26th, 2024 12:00 pm
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update - Nov 14th, 2024 9:30 pm
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference - Nov 4th, 2024 1:00 pm
Benitec Biopharma Announces Updated Investor Webcast Information - Oct 14th, 2024 10:00 am
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society - Oct 12th, 2024 10:30 am
Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc - Oct 1st, 2024 1:03 am
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans - Sep 28th, 2024 2:44 pm
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update - Sep 26th, 2024 8:30 pm
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society - Sep 18th, 2024 12:00 pm
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar - Sep 17th, 2024 12:00 pm
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study - Jul 15th, 2024 10:00 am
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors - Jul 1st, 2024 11:00 am
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update - May 13th, 2024 12:15 pm
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference - May 1st, 2024 12:00 pm
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study - Apr 18th, 2024 11:30 am